Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Gender
3.3. Snippet by Age Group
3.4. Snippet by Route of Administration
3.5. Snippet by Application
3.6. Snippet by Distribution Channels
3.7. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Diabetes and Advancements in Treatment Options
4.1.2. Restraints
4.1.2.1. High Treatment Costs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Saxagliptin
6.2.4. Sitagliptin
6.2.5. Linagliptin
6.2.6. Alogliptin
6.3. Alpha-glucosidase Inhibitors
6.3.1. Acarbose
6.3.2. Miglitol
6.4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists)
6.4.1. Dulaglutide
6.4.2. Exenatide
6.4.3. Liraglutide
6.4.4. Lixisenatide
6.4.5. Semaglutide
6.5. Sodium-glucose Transporter 2 (SGLT2) Inhibitors
6.5.1. Canagliflozin
6.5.2. Dapagliflozin
6.5.3. Empagliflozin
6.5.4. Ertugliflozin
6.6. Meglitinides
6.6.1. Repaglinide
6.6.2. Nateglinide
6.7. Sulfonylureas
6.7.1. Glipizide
6.7.2. Glimepiride
6.7.3. Glyburide
6.8. Thiazolidinediones
6.8.1. Rosiglitazone
6.8.2. Pioglitazone
6.9. Biguanides (Metformin)
6.10. Bile Acid sequestrants (Colesevelam)
6.11. Amylin Mimetics (Pramlintide)
7. By Gender
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
7.1.2. Market Attractiveness Index, By Gender
7.2. Male *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Female
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Up to 19 years*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. 20 – 65 years
8.4. Above 65 years
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
10. By Application
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Glycemic Control *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cardiovascular Safety
10.4. Hypoglycemia Avoidance
10.5. Others
11. By Distribution Channels
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11.1.2. Market Attractiveness Index, By Distribution Channels
11.2. Hospital Pharmacies *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.9.1. The U.S.
12.2.9.2. Canada
12.2.9.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.9.1. Germany
12.3.9.2. U.K.
12.3.9.3. France
12.3.9.4. Spain
12.3.9.5. Italy
12.3.9.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.9.1. Brazil
12.4.9.2. Argentina
12.4.9.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
12.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.9.1. China
12.5.9.2. India
12.5.9.3. Japan
12.5.9.4. South Korea
12.5.9.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Abbott *
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Medtronic
14.3. Dexcom, Inc.
14.4. AstraZeneca
14.5. TheracosBio, LLC
14.6. Boehringer Ingelheim International GmbH
14.7. Eli Lilly and Company.
14.8. Novo Nordisk A/S
14.9. Merck & Co., Inc.,
14.10. Pfizer Inc (*LIST NOT EXHAUSTIVE)
15. Appendix
15.1. About Us and Services
15.2. Contact Us